The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Open accessAbstract
Background: Multiple sclerosis is an acquired demyelinating disease of the central nervous system. It is the second most common cause of disability in adults in United States after head trauma. Discussion: The etiology of MS is probably multifactorial, related to genetic, environmental, and several other factors. The pathogenesis is not fully understood but is believed to involve T‐cell‐mediated inflammation directed against myelin and other related proteins with a possible role for B cells. The McDonald criteria have been proposed and revised over the years to guide the diagnosis of MS and are based on clinical presentation and magnetic resonance imaging (MRI) of the brain and spinal cord to establish dissemination in time and space. The treatment of MS includes disease modification with immunomodulator drugs and symptom management to address the specific symptoms such as fatigue, spasticity, and pain. Conclusion: An update on etiology, pathogenesis, diagnosis, and immunomodulatory treatment of MS is presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006) · JAMA · doi:10.1001/jama.296.23.2832 · Cited by 1,897
Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa073493 · Cited by 1,746
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Wucherpfennig, K. W., & Strominger, J. L. (1995) · Cell · doi:10.1016/0092-8674(95)90348-8 · Cited by 1,534
von Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells
Kleinewietfeld, M., Manzel, A., Titze, J., Kvakan, H., Yosef, N., Linker, R. A., Muller, D. N., & Hafler, D. A. (2013) · Nature · doi:10.1038/nature11868 · Cited by 1,394
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,242
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242
Tzartos, J. S., Friese, M. A., Craner, M. J., Palace, J., Newcombe, J., Esiri, M. M., & Fugger, L. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070690 · Cited by 1,187
Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion
Barnett, M. H., & Prineas, J. W. (2004) · Annals of Neurology · doi:10.1002/ana.20016 · Cited by 1,185
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
Inflammatory cortical demyelination in early multiple sclerosis.
Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100648 · Cited by 1,103
Vitamin D intake and incidence of multiple sclerosis
Munger, K. L., Zhang, S. M., O’Reilly, E., Hernán, M. A., Olek, M. J., Willett, W. C., & Ascherio, A. (2004) · Neurology · doi:10.1212/01.wnl.0000101723.79681.38 · Cited by 1,093
Environmental risk factors for multiple sclerosis. Part I: The role of infection
Ascherio, A., & Munger, K. L. (2007) · Annals of Neurology · doi:10.1002/ana.21117 · Cited by 1,042
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1
Wu, C., Yosef, N., Thalhamer, T., Zhu, C., Xiao, S., Kishi, Y., Regev, A., & Kuchroo, V. K. (2013) · Nature · doi:10.1038/nature11984 · Cited by 1,022
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,010
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Fujinami, R. S., & Oldstone, M. B. A. (1985) · Science · doi:10.1126/science.2414848 · Cited by 944
Sex ratio of multiple sclerosis in Canada: a longitudinal study
Orton, S.-M., Herrera, B. M., Yee, I. M., Valdar, W., Ramagopalan, S. V., Sadovnick, A. D., & Ebers, G. C. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70581-6 · Cited by 921
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Primary-progressive multiple sclerosis
Miller, D. H., & Leary, S. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70243-0 · Cited by 818
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054693 · Cited by 790
Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis
Simpson, S., Blizzard, L., Otahal, P., Van der Mei, I., & Taylor, B. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.240432 · Cited by 718
Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors
Ascherio, A., & Munger, K. L. (2007) · Annals of Neurology · doi:10.1002/ana.21141 · Cited by 714
Chiba, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., & Hoshino, Y. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.10.5037 · Cited by 596
Miller, D., Barkhof, F., Montalban, X., Thompson, A., & Filippi, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70071-5 · Cited by 594
New concepts in the immunopathogenesis of multiple sclerosis
Hemmer, B., Archelos, J. J., & Hartung, H.-P. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn784 · Cited by 580
Confavreux, C., O'Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Olsson, T. P., Wolinsky, J. S., Bagulho, T., Delhay, J.-L., Dukovic, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70308-9 · Cited by 579
Vitamin D and multiple sclerosis
Ascherio, A., Munger, K. L., & Simon, K. C. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70086-7 · Cited by 576
Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading
Miller, S. D., Vanderlugt, C. L., Begolka, W. S., Pao, W., Yauch, R. L., Neville, K. L., Katz-Levy, Y., Carrizosa, A., & Kim, B. S. (1997) · Nature Medicine · doi:10.1038/nm1097-1133 · Cited by 565
Immunomodulatory effects of Vitamin D in multiple sclerosis
Correale, J., Ysrraelit, M. C., & Gaitan, M. I. (2009) · Brain · doi:10.1093/brain/awp033 · Cited by 538
Monocyte/macrophage differentiation in early multiple sclerosis lesions
Brück, W., Porada, P., Poser, S., Rieckmann, P., Hanefeld, F., Kretzschmarch, H. A., & Lassmann, H. (1995) · Annals of Neurology · doi:10.1002/ana.410380514 · Cited by 530
The epidemiology of multiple sclerosis
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802973-2.00011-2 · Cited by 514
Grey matter pathology in multiple sclerosis
Geurts, J. J., & Barkhof, F. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70191-1 · Cited by 507
Primary progressive multiple sclerosis
Thompson, A. (1997) · Brain · doi:10.1093/brain/120.6.1085 · Cited by 506
Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis
Lucchinetti, C. F., Gavrilova, R. H., Metz, I., Parisi, J. E., Scheithauer, B. W., Weigand, S., Thomsen, K., Mandrekar, J., Altintas, A., Erickson, B. J., et al. (2008) · Brain · doi:10.1093/brain/awn098 · Cited by 493
Thalamic neurodegeneration in multiple sclerosis
Cifelli, A., Arridge, M., Jezzard, P., Esiri, M. M., Palace, J., & Matthews, P. M. (2002) · Annals of Neurology · doi:10.1002/ana.10326 · Cited by 490
Immunopathology of secondary‐progressive multiple sclerosis
Prineas, J. W., Kwon, E. E., Cho, E., Sharer, L. R., Barnett, M. H., Oleszak, E. L., Hoffman, B., & Morgan, B. P. (2001) · Annals of Neurology · doi:10.1002/ana.1255 · Cited by 453
Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions
Hauser, S. L., Bhan, A. K., Gilles, F., Kemp, M., Kerr, C., & Weiner, H. L. (1986) · Annals of Neurology · doi:10.1002/ana.410190610 · Cited by 399
Pathology of Demyelinating Diseases
Popescu, B. F. G., & Lucchinetti, C. F. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132443 · Cited by 397
Link, H., & Huang, Y.-M. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.07.006 · Cited by 396
Karussis, D. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.01.022 · Cited by 366
Interferon beta in the treatment of multiple sclerosis: Mechanisms of action
Wee Yong, V., Chabot, S., Stuve, O., & Williams, G. (1998) · Neurology · doi:10.1212/wnl.51.3.682 · Cited by 344
Environmental factors in multiple sclerosis
Ascherio, A. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.865866 · Cited by 330
Swanton, J. K., Rovira, A., Tintore, M., Altmann, D. R., Barkhof, F., Filippi, M., Huerga, E., Miszkiel, K. A., Plant, G. T., Polman, C., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70176-x · Cited by 330
Remyelinated Lesions in Multiple Sclerosis: Magnetic Resonance Image Appearance
Barkhof, F., Brück, W., De Groot, C. J. A., Bergers, E., Hulshof, S., Geurts, J., Polman, C. H., & van der Valk, P. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1073 · Cited by 328
Fingolimod for Multiple Sclerosis
Pelletier, D., & Hafler, D. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1101691 · Cited by 315
Filippi, M., Horsfield, M. A., Morrissey, S. P., MacManus, D. G., Rudge, P., McDonald, W. I., & Miller, D. H. (1994) · Neurology · doi:10.1212/wnl.44.4.635 · Cited by 314
HLA-DR2 Dose Effect on Susceptibility to Multiple Sclerosis and Influence on Disease Course
Barcellos, L. F., Oksenberg, J. R., Begovich, A. B., Martin, E. R., Schmidt, S., Vittinghoff, E., Goodin, D. S., Pelletier, D., Lincoln, R. R., Bucher, P., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/367781 · Cited by 293
Sodium intake is associated with increased disease activity in multiple sclerosis
Farez, M. F., Fiol, M. P., Gaitán, M. I., Quintana, F. J., & Correale, J. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307928 · Cited by 267
Pathology of Multiple Sclerosis: Where Do We Stand?
Popescu, B. F. G., Pirko, I., & Lucchinetti, C. F. (2013) · Continuum · doi:10.1212/01.con.0000433291.23091.65 · Cited by 261
Hafler, D. A., Slavik, J. M., Anderson, D. E., O'Connor, K. C., De Jager, P., & Baecher‐Allan, C. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00240.x · Cited by 260
Natalizumab for Multiple Sclerosis
Ransohoff, R. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmct071462 · Cited by 253
MRI criteria for MS in patients with clinically isolated syndromes
Montalban, X., Tintoré, M., Swanton, J., Barkhof, F., Fazekas, F., Filippi, M., Frederiksen, J., Kappos, L., Palace, J., Polman, C., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cec45c · Cited by 252
Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000
Mayr, W. T., Pittock, S. J., McClelland, R. L., Jorgensen, N. W., Noseworthy, J. H., & Rodriguez, M. (2003) · Neurology · doi:10.1212/01.wnl.0000094316.90240.eb · Cited by 243
Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis
Stadelmann, C., Ludwin, S., Tabira, T., Guseo, A., Lucchinetti, C. F., Leel-Össy, L., Ordinario, A. T., Brück, W., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh457 · Cited by 234
EPIDEMIOLOGY OF MULTIPLE SCLEROSIS
Weinshenker, B. G. (1996) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70257-7 · Cited by 232
The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis
Weinstock‐Guttman, B., Ransohoff, R. M., Kinkel, R. P., & Rudick, R. A. (1995) · Annals of Neurology · doi:10.1002/ana.410370105 · Cited by 225
Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials
Kappos, L., Weinshenker, B., Pozzilli, C., Thompson, A. J., Dahlke, F., Beckmann, K., Polman, C., & McFarland, H. (2004) · Neurology · doi:10.1212/01.wnl.0000145561.08973.4f · Cited by 224
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
Naismith, R. T., Piccio, L., Lyons, J. A., Lauber, J., Tutlam, N. T., Parks, B. J., Trinkaus, K., Song, S. K., & Cross, A. H. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24373 · Cited by 217
Management of Multiple Sclerosis
Rudick, R. A., Cohen, J. A., Weinstock-Guttman, B., Kinkel, R. P., & Ransohoff, R. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711273372207 · Cited by 201
Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes
Swanton, J. K. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.073247 · Cited by 200
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Filippini, G., Del Giovane, C., Vacchi, L., D'Amico, R., Di Pietrantonj, C., Beecher, D., & Salanti, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008933.pub2 · Cited by 186
PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
van Oosten, B. W., Killestein, J., Barkhof, F., Polman, C. H., & Wattjes, M. P. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215357 · Cited by 185
Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis
Dhib-Jalbut, S. (2002) · Neurology · doi:10.1212/wnl.58.8_suppl_4.s3 · Cited by 184
Smoking: effects on multiple sclerosis susceptibility and disease progression
Wingerchuk, D. M. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611425694 · Cited by 182
O'connor, K. C., Bar-Or, A., & Hafler, D. A. (2001) · Journal of Clinical Immunology · doi:10.1023/a:1011064007686 · Cited by 180
Disability in multiple sclerosis: A reference for patients and clinicians
Kister, I., Chamot, E., Salter, A. R., Cutter, G. R., Bacon, T. E., & Herbert, J. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872855 · Cited by 176
Mechanisms of immunomodulation by glatiramer acetate
Gran, B., Tranquill, L. R., Chen, M., Bielekova, B., Zhou, W., Dhib–Jalbut, S., & Martin, R. (2000) · Neurology · doi:10.1212/wnl.55.11.1704 · Cited by 158
Pathophysiology of multiple sclerosis and the place of teriflunomide
Gold, R., & Wolinsky, J. S. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01444.x · Cited by 144
Treatment of Acute Relapses in Multiple Sclerosis
Berkovich, R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0160-7 · Cited by 134
Glatiramer acetate for multiple sclerosis
Mantia, L. L., Munari, L., & Lovati, R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004678.pub2 · Cited by 126
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety
Fox, R. J., Kita, M., Cohan, S. L., Henson, L. J., Zambrano, J., Scannevin, R. H., O'Gorman, J., Novas, M., Dawson, K. T., & Phillips, J. T. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.849236 · Cited by 124
Multiple sclerosis: New insights and trends
Koriem, K. M. M. (2016) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2016.03.009 · Cited by 112
Management of worsening multiple sclerosis with mitoxantrone: A review
Fox, E. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.04.013 · Cited by 102
Immune-mediated CNS diseases: A review on nosological classification and clinical features
Zettl, U. K., Stüve, O., & Patejdl, R. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.05.008 · Cited by 101
The spectrum of multiple sclerosis: new lessons from pathology
Brück, W., & Stadelmann, C. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000169736.60922.20 · Cited by 101
Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis
Awad, A. M., Hemmer, B., Hartung, H.-P., Kieseier, B. C., Bennett, J. L., & Stüve, O. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.09.002 · Cited by 97
Emerging concepts in autoimmune encephalomyelitis beyond the CD4/TH1 paradigm
Batoulis, H., Addicks, K., & Küerten, S. (2010) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2010.06.006 · Cited by 73
Immunopathology or Organ‐Specific Autoimmunity as a Consequence of Virus Infection
Aichele, P., Bachmann, M. F., Hengartner, H., & Zinkernagel, R. M. (1996) · Immunological Reviews · doi:10.1111/j.1600-065x.1996.tb00909.x · Cited by 66
Is inflammation important in early PPMS? a longitudinal MRI study
Ingle, G. T. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.036590 · Cited by 66
Glatiramer Acetate in Multiple Sclerosis: A Review
Ruggieri, M., Avolio, C., Livrea, P., & Trojano, M. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00010.x · Cited by 64
Sudden unexpected death on fingolimod
Lindsey, J. W., Haden‐Pinneri, K., Memon, N., & Buja, L. M. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512438456 · Cited by 63
Foley, J. F., Stoker, E., & Damal, K. (2013) · Biologics · doi:10.2147/btt.s53007 · Cited by 50
Glatiramer acetate in multiple sclerosis
Mezzapesa, D. M., Rovaris, M., & Filippi, M. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.4.451 · Cited by 45
Update on immunopathogenesis and immunotherapy in multiple sclerosis
Hemmer, B., & Selter (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s31813 · Cited by 42
Conradi, S., Malzahn, U., Schröter, F., Paul, F., Quill, S., Spruth, E. J., Harms, L., Bergh, F. T., Ditzenbach, A., Georgi, T., et al. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-123 · Cited by 39
Sotgiu, S., Maura, P., Alessandra, S., Sanna, A., & Giulio, R. (2003) · Autoimmunity · doi:10.1080/0891693031000151607 · Cited by 38
Genetics and Natural History of Multiple Sclerosis
Kantarci, O. H. (2008) · Seminars in Neurology · doi:10.1055/s-2007-1019125 · Cited by 33
Multiple sclerosis: it epidemiological, genetic, and health care impact.
Williams, R., Rigby, A. S., Airey, M., Robinson, M. R. G., & Ford, H. L. (1995) · Journal of Epidemiology & Community Health · doi:10.1136/jech.49.6.563 · Cited by 29
Modifiable environmental factors in multiple sclerosis
Fragoso, Y. D. (2014) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20140159 · Cited by 27
Sobel, R. A., & Moore, G. W. (2008) · CRC Press eBooks · doi:10.1201/b13319-21 · Cited by 22
An update on multiple sclerosis
Hauser, S. L. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.10.007 · Cited by 8
IMMUNOPATHOGENESIS OF MULTIPLE SCLEROSIS
Yong, V. W. (2004) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000293630.92979.c9 · Cited by 3
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
Cited by
Impact of Metabolic Syndrome on Neuroinflammation and the Blood–Brain Barrier
Van Dyken, P., & Lacoste, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00930 · Cited by 359
Epidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M., Benedict, R. H. B., Zivadinov, R., & Weinstock-Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 306
Melatonin as an anti-inflammatory agent modulating inflammasome activation
Favero, G., Franceschetti, L., Bonomini, F., Rodella, L. F., & Rezzani, R. (2017) · International Journal of Endocrinology · doi:10.1155/2017/1835195 · Cited by 233
Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets
Govindarajan, V., de Rivero Vaccari, J. P., & Keane, R. W. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01944-9 · Cited by 110
Broos, J. Y., van der Burgt, R. T. M., Konings, J., Rijnsburger, M., Werz, O., de Vries, H. E., Giera, M., & Kooij, G. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02981-w · Cited by 41
Metadata
- Authors
- Garg, N., & Smith, T. W.
- Venue
- Brain and Behavior
- Publisher
- Wiley
- Published
- 2015-08-03
- Volume
- 5
- Issue
- 9
- Pages
- e00362-e00362
- ISSN
- 2157-9032 (ISSN-L)
- 2162-3279
- OpenAlex
- W1825094415
- Cited by
- 348
- References
- 111
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.